CD19-directed CAR T cells gain traction

[...]there is reason for optimism about long-term outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma who achieve complete remission after anti-CD19 CAR T-cell therapy. [...]irrespective of these differences, what is remarkable across anti-CD19 CAR T-cell trials in relaps...

Full description

Saved in:
Bibliographic Details
Published in:The lancet oncology 2019-01, Vol.20 (1), p.2-3
Main Author: Schuster, Stephen J
Format: Article
Language:English
Subjects:
Antigens, CD19 - therapeutic use
B-cell lymphoma
CD19 antigen
Chemotherapy
Clinical trials
Cytokines
FDA approval
Humans
Immunotherapy
Immunotherapy, Adoptive
Lymphocytes B
Lymphocytes T
Lymphoma
Lymphoma, B-Cell
Medical prognosis
Patients
Remission
T-Lymphocytes - immunology
Traction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]there is reason for optimism about long-term outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma who achieve complete remission after anti-CD19 CAR T-cell therapy. [...]irrespective of these differences, what is remarkable across anti-CD19 CAR T-cell trials in relapsed or refractory diffuse large B-cell lymphoma is the consistent durability of responses, with ongoing responses in 39 (39%) of 101 patients at a median of 27·1 months' follow-up in ZUMA-15 and 35 (35%) of 99 patients at a median of 19·3 months' follow-up in JULIET;3 the emergence of plateaus in curves for response duration and progression-free survival beyond 6 months; the absence of late or unexpected gene-therapy-related events; and the unique but manageable toxicities (ie, cytokine release syndrome and neurotoxicity1,3,5,7). In addition to long-term safety, evidence of B-cell recovery during these sustained remissions was also noted (as in Locke and colleagues' study5), with evidence of immunoglobulin recovery in some patients too.7 When assessing the potential therapeutic effects of CD19-directed CAR T-cell therapies on prognosis for relapsed or refractory diffuse large B-cell lymphoma, it will be necessary to identify the subsets of patients who will benefit from this treatment.
ISSN:1470-2045
1474-5488
DOI:10.1016/S1470-2045(18)30900-8